Global Information
회사소개 | 문의 | 비교리스트

AVR-RD-01 : 신약 인사이트와 시장 예측(2030년)

AVR RD 01 - Emerging Drug Insight and Market Forecast - 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 09월 상품 코드 959696
페이지 정보 영문 50 Pages
가격
US $ 3,250 ₩ 3,819,000 PDF (Single User License)
US $ 6,500 ₩ 7,638,000 PDF (Site License)
US $ 9,750 ₩ 11,458,000 PDF (Global License)


AVR-RD-01 : 신약 인사이트와 시장 예측(2030년) AVR RD 01 - Emerging Drug Insight and Market Forecast - 2030
발행일 : 2020년 09월 페이지 정보 : 영문 50 Pages

AVROBIO가 연구개발을 진행시키고 있는 파브리병 유전자 치료제 AVR-RD-01은 현재 2개 임상시험이 실행되고 있습니다. 캐나다에서의 제I상 시험에서는 5명의 피험자에게 투약하고 있으며, 호주, 미국, 캐나다에서 행해지고 있는 제II상 임상시험에서는 4명의 피험자에게 투약하고 있습니다.

미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본 주요 7개국의 AVR-RD-01 시장을 조사했으며, 2030년까지 전망을 제시하고, 의약품 개요, 시장 평가, SWOT 분석, 경쟁사 각사 개요, 기타 새로운 치료제 등의 정보를 제공합니다.

조사 범위:

  • 제품 설명, 작용기서, 투여량과 투여 방법, 연구개발 활동을 포함한 종합적인 제품 개요
  • 규제기관 승인 절차 마일스톤 등 개발 활동 상세
  • 미국 , 유럽, 일본의 의약품 연구개발 상세
  • AVR-RD-01에 관한 유효기간을 포함한 특허 정보
  • 2030년까지 AVR-RD-01 매출 예측
  • 개발 후기 단계(제III상)에 있는 파브리병 새로운 치료제의 종합적인 정보
  • 애널리스트의 견해와 SWOT 분석

보고서 하이라이트:

  • 파브리병 치료제 시장 시나리오는 세계 각국에서 진행되고 있는 연구개발과 의료비 증가로 크게 변화하고, 시장 규모 확대에 의해 참여하는 제약회사가 증가할 전망입니다.
  • 기업과 연구자는 AVR-RD-01 우위성을 높일 기회를 모색하고 있습니다. 현재 개발중인 치료법에서는 병상을 치료/개선하기 위한 새로운 어프로치가 초점이 되고 있습니다.
  • AVR-RD-01으로 경쟁하는 새로운 경쟁 제품이 등장하고 있으며, 조만간 시장에 큰 영향을 미칠 것으로 생각됩니다.

본 보고서에서 대응하고 있는 주요 의문점:

  • AVR-RD-01을 개발하고 있는 것은 어느 기업인가?
  • AVR-RD-01 개발에 이용되고 있는 기술은 무엇인가?
  • AVR-RD-01 제품 종류, 투여 경로, 작용기서는 어떠한 것인가?
  • 임상시험 상황과 완료일은 언제인가?
  • AVR-RD-01 개발과 관련된 주요 협력, 합병, 인수, 라이선싱 등의 움직임은 어떻게 되고 있는가?
  • AVR-RD-01에 부여된 주요 지정은 무엇인가?
  • AVR-RD-01 예측 시장 시나리오는 어떠한 것인가?
  • AVR-RD-01의 지금까지 움직임과 향후 전망은 어떻게 되는가?
  • 미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본에서의 AVR-RD-01 매출 예측은 어떻게 되는가?
  • 이용 가능한 기타 신제품은 무엇인가? 또한 이러한 제품은 어떠한 형태로 경쟁하는가?
  • 현재 개발 후기 단계 새로운 치료제는 무엇인가?

목차

제1장 의약품 개요

  • 제품 상세
  • 작용기서
  • 투약과 관리
  • 연구개발 활동
    • 임상 개발
    • 안전성과 유효성
  • 기타 개발 활동

제2장 시장 평가

  • 주요 7개국 시장 분석
  • 미국 시장
  • 독일 시장
  • 프랑스 시장
  • 이탈리아 시장
  • 스페인 시장
  • 영국 시장
  • 일본 시장

제3장 SWOT 분석

제4장 애널리스트의 견해

제5장 시장에서의 경쟁

제6장 기타 새로운 치료제

제7장 부록

제8장 보고서 구입 옵션

KSM 20.09.16

List of Tables

  • Table 1 AVR RD 01, Description
  • Table 2 AVR RD 01, Clinical Trial Description
  • Table 3 AVR RD 01, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of AVR RD 01
  • Figure 2 Patent Details, AVR RD 01
  • Figure 3 AVR RD 01, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 AVR RD 01, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 AVR RD 01, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 AVR RD 01, Japan Market Size from 2020 to 2030 (in Millions USD)

"AVR RD 01 - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Fabry Disease in 7 Major Markets. A detailed picture of the AVR RD 01 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

AVROBIO's investigational gene therapy for Fabry disease is currently being studied in two clinical trials. An investigator-sponsored Phase 1 trial in Canada is fully enrolled, with five patients dosed. The trial is initiated: FAB-201, the Phase 2 trial, has dosed four treatment-naive patients through December 2019 and continues to enroll in Australia, the U.S. and Canada.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around AVR RD 01.
  • The report contains forecasted sales for AVR RD 01 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Fabry Disease.
  • The report also features the SWOT analysis with analyst insights and key findings of AVR RD 01.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AVR RD 01 Analytical Perspective by DelveInsight

  • In-depth AVR RD 01 Market Assessment

This report provides a detailed market assessment of AVR RD 01 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • AVR RD 01 Clinical Assessment

The report provides the clinical trials information of AVR RD 01 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Fabry Disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence AVR RD 01 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Fabry Disease are giving market competition to AVR RD 01 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of AVR RD 01.
  • Our in-depth analysis of the forecasted sales data of AVR RD 01 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AVR RD 01.

Key Questions:

  • Which company is developing AVR RD 01 along with the phase of the clinical study?
  • What is the technology utilized in the development of AVR RD 01?
  • What is the product type, route of administration and mechanism of action of AVR RD 01?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AVR RD 01 development?
  • What are the key designations that have been granted to AVR RD 01?
  • What is the forecasted market scenario of AVR RD 01?
  • What is the history of AVR RD 01 and what is its future?
  • What is the forecasted sales of AVR RD 01 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to AVR RD 01?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

Back to Top
전화 문의
F A Q